NasdaqHealth CareBiological Products, (No Diagnostic Substances)NEW HAVEN, CT

IRulya Therapeutics Inc. IRLA

Ask your AI

Estimated market cap $431.49M10.84M shares, shares as of Nov 5, 2026CIK 1662774

Insider trades, 12 mo

0 buys · 1 sell

$173.5K sold, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

0.8% of shares · 6 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in IRulya Therapeutics Inc.'s latest quarterly report, compared with the one before.

Filed Nov 13, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in IRulya Therapeutics Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

1 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Dec 26, 2025. Insiders have two business days to file.

Recent insider trades
Insider	Traded	Type	Value	Since trade
Luca Benatti Director	Dec 26, 2025 Form 4 ↗	Sale	−$173.5K 50,000 sh @ $3.47	-103.7%

All IRLA insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

88,809 shares

20 funds report IRLA. Values checked against market prices.

Funds own 0.1% of shares (Q1 2026)

1 fund holds the stock.

Q3 2026: 0.8% · 5,560 of ~8,900 funds reported so far

Q4 20250.2%
Q1 20260.1%
Q3 2026 (so far)0.8%

Q3 2026. 7 new, 6 added to, 4 trimmed, 15 exited since Q2 2026.

Top 13F holders
#
1	Birchview Capital, LP 13F ↗	40,601	$1.3M	New
2	Jane Street Group, LLC 13F ↗	20,156	$625.0K	+59.4%
3	Geode Capital Management, LLC 13F ↗	9,741	$302.1K	New
4	Vanguard Capital Management LLC 13F ↗	9,216	$285.8K	-23.5%
5	Vanguard Fiduciary Trust Co 13F ↗	5,372	$166.6K	+48.6%
6	BlackRock, Inc. 13F ↗	1,689	$52.4K	-0.8%
7	JPMorgan Chase & Co 13F ↗	792	$24.7K	+39500.0%
8	Morgan Stanley 13F ↗	794	$24.6K	-80.6%
9	Group One Trading LLC 13F ↗	234	$7,256	New
10	Gen-Wealth Partners Inc 13F ↗	166	$5,148	+0.6%

Download CSV Every fund that holds IRLA, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What IRulya Therapeutics Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What IRulya Therapeutics Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report, adjusted for splits

Funds holding the stock by quarter

Q4 2025	1	—	471	$315.6K
Q1 2026	1	0	471	$9,552
Q2 2026	28	+27	330,076	$17.3M
Q3 2026	20	-8	88,809	$2.8M

Each point is a quarter-end, from Q4 2025 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (22053A305). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q4 2025) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits (1-for-10 on Apr 13, 2026, 1-for-20 on Jun 30, 2026): reports from before a split are multiplied by its ratio, so every quarter is on the share count of Q3 2026.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes11 in 12 mo 8-K events9 in 90 days PatentsNone on record Short interestFINRA · updated Oct 15 Planned insider salesForm 144 · 3 in 12 mo Executive pay3 fiscal years Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials2 active IPO history2 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: IRulya Therapeutics Inc.
Address: 101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT 06510
Phone: 203-208-8994
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company
Incorporated in: DE
Listed as: IRLA (Nasdaq)
Former names: Quince Therapeutics, Inc. (until 2026); Cortexyme, Inc. (until 2022)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$39.80+$0.02 (+0.05%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $27.87 · High $40.27Nov 13, 2026

Aug 13, 2026Low $26.72 · High $40.27Nov 13, 2026

Nov 13, 2025Low $16.00 · High $880.00Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. The stock split 1-for-20 on Jun 30, 2026; 1-for-10 on Apr 13, 2026; earlier prices are shown divided by the split ratio. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.